SEC Form 4 · accession 0000899243-18-027585
MELINTA THERAPEUTICS, INC. /NEW/ · MLNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Johnson
Officer — Interim CEO · Director
Period of report
Oct 26, 2018
Accepted (ET)
Oct 29, 2018 · 5:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001461993
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $2.80 | Oct 26, 2018 | A | 150,000 | A | — | Oct 26, 2028 | Common Stock | 150,000 | 150,000 | D |
| Restricted Stock UnitsF2 | $0.00 | Oct 26, 2018 | A | 50,000 | A | — | — | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The award vests in equal monthly installments over a period of 12 months from October 18, 2018, subject to the Reporting Person continuing to provide services in any capacity (including, but not limited to, service as a member of the Board of Directors).
- F2The award vests in full and will be settled on October 18, 2019, subject to the Reporting Person continuing to provide services in any capacity (including, but not limited to, service as a member of the Board of Directors).